Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. develops, markets and sells health and wellness products through a secure telemedicine platform under the MangoRx and PeachesRx brands. Company news commonly covers telehealth programs for erectile dysfunction, hair growth, hormone replacement therapy and weight management, including prescription access and fulfillment through pharmacy partners when medically appropriate.
Recurring updates also include product and intellectual-property developments such as MGX-0024, an antiviral animal feed and drinking water additive technology, as well as capital actions, platform operations and legal matters involving technology vendors. The company’s releases often connect its wellness brands, digital consultation model and eCommerce infrastructure to new treatment categories and operating initiatives.
Summary not available.
Mangoceuticals (NASDAQ: MGRX) filed a PCT international application (P-641039-PC) on February 26, 2026 to seek global patent protection for its antiviral animal feed and drinking water additive technology that powers MGX-0024.
The filing claims priority to U.S. provisional 63/763,785 (Feb 26, 2025), extends protection to 150+ countries, and cites zero respiratory mortality in 29,000 commercial birds plus significant prophylactic benefit versus H5N1 in a controlled challenge study. U.S. protection remains under Patent No. 11,517,523 with national patents granted or pending in major jurisdictions.
Mangoceuticals (NASDAQ: MGRX) reported that its antiviral MGX-0024 produced zero respiratory-related mortality across approximately 29,000 treated broiler chickens in three independent commercial field trials, versus an expected ~50% (≈14,500) respiratory mortality in untreated historical/comparator flocks. A controlled BSL-3 H5N1 challenge showed up to 60% mortality reduction (2/7 vs 5/7) and extended mean time-to-death to 10.71 days from 5.86 days. MGX-0024 is a GRAS-classified polyphenol-plus-zinc formulation, covered by U.S. Patent No. 11,517,523 and corresponding international patents. Company emphasizes further validation, larger field trials, and regulatory engagement before any approved veterinary use.
Mangoceuticals (NASDAQ: MGRX) reported early traction for a newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) program priced at $99/month. MangoRx cites 336% month-over-month sales growth since mid-December and a 54% reduction in customer acquisition cost.
The offer includes doctor visits, labs, and prescribed medication. Management expects TRT to be the primary near-term growth driver while expanding telehealth men’s health services and maintaining regulatory compliance.
Mangoceuticals (NASDAQ: MGRX) closed a registered direct offering and concurrent private placement on December 19, 2025, raising approximately $2.5 million in gross proceeds.
The company sold 1,930,502 Common Units (or Pre-Funded Units) at an offering price of $1.295 per Common Unit (or $1.29499 per Pre-Funded Unit) and issued accompanying PIPE Common Warrants exercisable at $1.4245. Pre-funded warrants are immediately exercisable.
Proceeds are expected to be used for general corporate purposes and working capital. Aegis Capital acted as placement agent; the offering was made under an effective Form S-3 shelf declared effective June 24, 2025.
Mangoceuticals (NASDAQ: MGRX) announced an up to $100 million Solana-focused digital asset treasury (DAT) strategy on Dec 19, 2025 in partnership with Cube Group and a new subsidiary, Mango DAT, LLC.
The MULTI-DAT framework targets staking and DeFi yield with staked 7-8% APY and active management targeting 8-20% APY, and names Cube Group founders (Solana core developers) as asset manager. The company may use its shelf registration and ATM or other offerings to fund accumulation; no guarantee of full funding was stated.
Mangoceuticals (NASDAQ: MGRX) entered definitive agreements for a registered direct offering and a concurrent private placement expected to raise approximately $2.5 million. The transactions consist of the sale of 1,930,502 Common Units (or Pre-Funded Units), each including one share or one pre-funded warrant plus one PIPE Common Warrant to buy one share at an exercise price of $1.4245. The offering price per Common Unit is $1.295 (Pre-Funded Unit $1.29499). The offerings are priced at the market under Nasdaq rules and are expected to close on or about December 19, 2025, subject to customary conditions. Proceeds are intended for general corporate purposes and working capital. The registered offering relies on an effective Form S-3 declared effective June 24, 2025, and the company has agreed to registration rights for resale of issued securities.
Mangoceuticals (NASDAQ: MGRX) clarified that its newly launched MangoRx Direct and PeachesRx Direct weight-management programs are live as of November 14, 2025, offering telehealth consultations, personalized care plans, and ongoing support for $99 per month (medication cost separate).
Through a vetted third-party provider, the programs can facilitate valid prescriptions for FDA-approved branded GLP-1 medications, including Zepbound and Wegovy, and patients may fill prescriptions at any licensed pharmacy or manufacturer self-pay channels, subject to manufacturer supply availability. Mangoceuticals confirmed it has no direct contract with Eli Lilly or Novo Nordisk.
Mangoceuticals (NASDAQ: MGRX) launched MangoRx Direct and PeachesRx Direct on Nov 13, 2025 to provide telehealth access, clinical monitoring, and fulfillment for branded GLP-1 obesity drugs Zepbound (tirzepatide) via LillyDirect and Wegovy (semaglutide) via NovoCare. The company offers a medication-management membership at $99/month and states GLP-1 drugs are available at fixed cash-pay pricing starting $499/month with home delivery or local pharmacy pickup.
The release also notes a Novo Nordisk spokesperson saying Novo Nordisk has no agreement with Mangoceuticals, and references White House pricing initiatives targeting $245/month government prices and other program pricing changes in 2026.